Recombinant Microbial Expression System for High-Yield Production of Vaccine Antigens in Industrial Bioreactors

Abstract

The increasing demand of vaccines in the world has aggravated the necessity to have effective and scalable production platforms 
that can produce high quality vaccine antigens. Recombinant microbial expression systems have been identified as the possible 
alternatives to traditional vaccine production techniques gain their important role of rapid growth, low costs, and potential 
production of higher amounts of recombinant proteins. But issues like low antigen titer, low expression efficiency, high production 
costs and scalability limitation remain to be a drawback in the industrial scale of producing vaccine antigen. In this study, a 
recombinant microbial expression system is proposed to improve the production of vaccine antigens in large quantities in industrial 
bioreactors by optimizing the selection of a host, expression vectors design, fermentation medium, and subsequently cleaning the 
product by downstream purification. This study design involves the selection of antigen genes, recombinant vectors, transformation 
of microbial hosts, fermentation in bioreactor and recovery of antigens and performance assessment. Key performance metrics 
such as antigen yield, expression efficiency, productivity, purity, recovery rate, scalability index, and cost efficiency, were used to 
evaluate the proposed system. The experimental analysis revealed that all performance parameters were largely improved, as the 
antigen yield was increased to 850mg/L, the expression efficiency was enhanced to 92, the productivity was doubled to 24mg/L/h 
and the purity was raised to 97. Moreover, the system was developed to be accorded improved scalability and cost of production 
was cut by 35 percent as against the traditional methods of production. These discoveries mean that the antigen microbial 
expression system proposed can be a highly sound and cost-effective system to produce large quantities of vaccines antigens and 
to continue the development of industrial biotechnology and the production of the next-generation vaccines.